Oncolytics Biotech Stock Performance
| ONCY Stock | USD 0.89 0.05 5.46% |
The company holds a Beta of 2.24, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Oncolytics Biotech will likely underperform. At this point, Oncolytics Biotech has a negative expected return of -0.27%. Please make sure to check Oncolytics Biotech's maximum drawdown, as well as the relationship between the daily balance of power and period momentum indicator , to decide if Oncolytics Biotech performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Oncolytics Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's fundamental indicators remain fairly strong which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Last Split Factor 10:95 | Dividend Date 2018-05-25 | Last Split Date 2018-05-25 |
1 | Oncolytics Biotech Inc. Given Consensus Rating of Moderate Buy by Brokerages - MarketBeat | 12/01/2025 |
2 | Insider Trading | 12/31/2025 |
3 | Oncolytics Biotech Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen OReilly, Dr. Neil Segal, and Dr. Van Morris | 01/07/2026 |
4 | Oncolytics Biotech Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada | 01/09/2026 |
5 | Oncolytics Biotech Leadership Strengthens As Pelareorep Advances | 01/12/2026 |
6 | Oncolytics Biotech Announces Results of Special Meeting of Shareholders | 01/15/2026 |
7 | ONCY stock is up 20 percent today. Heres what we see in our data. - Quiver Quantitative | 01/21/2026 |
8 | THE RESILIENCE DOCTRINE 5 Assets Securing the 2026 Sovereign Stack | 01/26/2026 |
9 | Late-Stage Breakthroughs How 2026s Top Clinical Platforms Are Redefining Cancer Treatment | 01/28/2026 |
| Begin Period Cash Flow | 34.9 M | |
| Total Cashflows From Investing Activities | -239 K |
Oncolytics | Build AI portfolio with Oncolytics Stock |
Oncolytics Biotech Relative Risk vs. Return Landscape
If you would invest 107.00 in Oncolytics Biotech on November 8, 2025 and sell it today you would lose (23.00) from holding Oncolytics Biotech or give up 21.5% of portfolio value over 90 days. Oncolytics Biotech is currently does not generate positive expected returns and assumes 5.2535% risk (volatility on return distribution) over the 90 days horizon. In different words, 47% of stocks are less volatile than Oncolytics, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Oncolytics Biotech Target Price Odds to finish over Current Price
The tendency of Oncolytics Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.89 | 90 days | 0.89 | about 92.59 |
Based on a normal probability distribution, the odds of Oncolytics Biotech to move above the current price in 90 days from now is about 92.59 (This Oncolytics Biotech probability density function shows the probability of Oncolytics Stock to fall within a particular range of prices over 90 days) .
Oncolytics Biotech Price Density |
| Price |
Predictive Modules for Oncolytics Biotech
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Oncolytics Biotech. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Oncolytics Biotech's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Oncolytics Biotech Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Oncolytics Biotech is not an exception. The market had few large corrections towards the Oncolytics Biotech's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Oncolytics Biotech, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Oncolytics Biotech within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.47 | |
β | Beta against Dow Jones | 2.24 | |
σ | Overall volatility | 0.08 | |
Ir | Information ratio | -0.08 |
Oncolytics Biotech Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Oncolytics Biotech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Oncolytics Biotech can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Oncolytics Biotech generated a negative expected return over the last 90 days | |
| Oncolytics Biotech has high historical volatility and very poor performance | |
| Oncolytics Biotech has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (31.71 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Oncolytics Biotech currently holds about 32.36 M in cash with (26.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.55. | |
| Oncolytics Biotech has a poor financial position based on the latest SEC disclosures | |
| Latest headline from prnewswire.com: Late-Stage Breakthroughs How 2026s Top Clinical Platforms Are Redefining Cancer Treatment |
Oncolytics Biotech Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Oncolytics Stock often depends not only on the future outlook of the current and potential Oncolytics Biotech's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Oncolytics Biotech's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 76.5 M | |
| Cash And Short Term Investments | 15.9 M |
Oncolytics Biotech Fundamentals Growth
Oncolytics Stock prices reflect investors' perceptions of the future prospects and financial health of Oncolytics Biotech, and Oncolytics Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Oncolytics Stock performance.
| Return On Equity | -7.69 | ||||
| Return On Asset | -1.11 | ||||
| Current Valuation | 88.4 M | ||||
| Shares Outstanding | 107.61 M | ||||
| Price To Earning | (2.06) X | ||||
| Price To Book | 1,149 X | ||||
| EBITDA | (34.88 M) | ||||
| Net Income | (31.71 M) | ||||
| Cash And Equivalents | 32.36 M | ||||
| Cash Per Share | 0.55 X | ||||
| Total Debt | 1.06 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 10.42 X | ||||
| Book Value Per Share | 0.0007 X | ||||
| Cash Flow From Operations | (26.97 M) | ||||
| Earnings Per Share | (0.27) X | ||||
| Market Capitalization | 90.02 M | ||||
| Total Asset | 20.19 M | ||||
| Retained Earnings | (477.71 M) | ||||
| Working Capital | 12.19 M | ||||
| Current Asset | 14.39 M | ||||
| Current Liabilities | 2.91 M | ||||
About Oncolytics Biotech Performance
Evaluating Oncolytics Biotech's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Oncolytics Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Oncolytics Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.81) | (1.72) | |
| Return On Capital Employed | (2.98) | (2.83) | |
| Return On Assets | (1.81) | (1.72) | |
| Return On Equity | (4.77) | (4.53) |
Things to note about Oncolytics Biotech performance evaluation
Checking the ongoing alerts about Oncolytics Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Oncolytics Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Oncolytics Biotech generated a negative expected return over the last 90 days | |
| Oncolytics Biotech has high historical volatility and very poor performance | |
| Oncolytics Biotech has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (31.71 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Oncolytics Biotech currently holds about 32.36 M in cash with (26.97 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.55. | |
| Oncolytics Biotech has a poor financial position based on the latest SEC disclosures | |
| Latest headline from prnewswire.com: Late-Stage Breakthroughs How 2026s Top Clinical Platforms Are Redefining Cancer Treatment |
- Analyzing Oncolytics Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Oncolytics Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Oncolytics Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Oncolytics Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Oncolytics Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Oncolytics Biotech's stock. These opinions can provide insight into Oncolytics Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Oncolytics Stock Analysis
When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.